Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

Figure 4

The effects of YSL plus mid-dose doxorubicin on the internal organs of nude mice bearing human hepatocellular carcinoma BEL-7402 tumors. BEL-7402 cell (1 × 107/every mouse) was subcutaneously inoculated into the right back of every nude mouse. When the tumors had reached an average volume of 100 mm3, the tumor-bearing nude mice were randomly divided into different groups (n = 12). The mice were administrated i.p. 30 days. At the next day of the last administration, nude mice were sacrificed, and then put the heart, liver and kidney tissue into 10% formalin to fix and paraffin-embedded sections of each tissue sample were stained routinely with hematoxylin and eosin (HE). Figures 4A, 4B, 4C and 4D are heart samples. Figures 4E, 4F, 4G, and 4H are liver samples. Figures 4I, 4J, 4K and 4L are kidney samples. Figure 4A (Mid-dose doxorubicin): Myocardial cells are pultaceous and characterized by enhanced acidophilia. Figure 4B (YSL plus mid-dose doxorubicin): The transverse striation of myocardial cells is clear and with good repair. Figure 4C (YSL group) and Figure 4D (Saline group): There are no obvious abnormalities. Figure 4E (Mid-dose doxorubicin): There was enhanced acidophilia and interstitial edema. Figure 4F (YSL plus mid-dose doxorubicin): The structure of hepatic lobules is clear. Figure 4G (YSL group) and Figure 4H (Saline group): There are no obvious abnormalities. Figure 4I (Mid-dose doxorubicin): There are congestion of renal glomeruli and narrowed Bowman's space. Figure 4J (YSL plus mid-dose doxorubicin): Nephric tubules exhibit swelling. Figure 4K (YSL group) and Figure 4L (Saline group): There are no obvious abnormalities.

Back to article page